Development of BSL-2 Neutralization Assays to Evaluate Filovirus Vaccines

National Institute Of Allergy And Infectious Diseases

Investigators

Abstract

This IAA will support the development of neutralization assays based on recombinant VSV constructs containing the Filovirus glycoprotein to assess vaccine efficacy, as well as support the identification of Zaire-Ebola virus neutralizing epitopes as surrogate markers of vaccine efficacy to the other genera of the Filoviridae.